Highlights and Quick Summary
- Depreciation & Amortization Growth for the quarter ending September 29, 2021 was -7.2% (a -117.36% decrease compared to previous quarter)
- Year-over-year quarterly Depreciation & Amortization Growth decreased by -102.36%
- Annual Depreciation & Amortization Growth for 2020 was 220.82% (a 1446.36% increase from previous year)
- Annual Depreciation & Amortization Growth for 2019 was 14.28% (a -18.82% decrease from previous year)
- Annual Depreciation & Amortization Growth for 2018 was 17.59% (a -32.96% decrease from previous year)
- Twelve month Depreciation & Amortization Growth ending September 29, 2021 was 75.12% (a -58.41% decrease compared to previous quarter)
- Twelve month trailing Depreciation & Amortization Growth decreased by -65.98% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
| 29 Sep '21 | 29 Jun '21 | 30 Mar '21 | 30 Dec '20 |
|---|---|---|---|
| 75.12% | 180.61% | 292.04% | 220.82% |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Depreciation & Amortization Growth of AbbVie Inc.
Most recent Depreciation & Amortization Growthof ABBV including historical data for past 10 years.Interactive Chart of Depreciation & Amortization Growth of AbbVie Inc.
AbbVie Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | -7.2% | 41.48% | 296.24% | – | – |
| 2020 | 305.7% | 355.67% | 209.76% | 11.13% | 220.82% |
| 2019 | 15.16% | 15.63% | 13.32% | 13.03% | 14.28% |
| 2018 | 19.78% | 14.78% | 16.89% | 18.98% | 17.59% |
| 2017 | 12.5% | 24.67% | 31.14% | 39.55% | 26.24% |
| 2016 | 25.67% | 33.92% | 52.11% | 69.62% | 42.22% |
| 2015 | 35.23% | 18.23% | -5.94% | -20.6% | 6.36% |
| 2014 | -3.5% | -17.95% | -14.41% | -12.33% | -12.37% |
| 2013 | -35.28% | 3.08% | -20.0% | -28.84% | -22.0% |
| 2012 | -4.89% | -27.99% | -7.12% | 1.44% | -9.59% |
| 2011 | – | – | -72.57% | -54.8% | 7.43% |
| 2010 | – | – | – | – | 69.75% |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.